• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    S&P 500, Nasdaq 100 Aim For 8th Week Of Gains As Fed's Inflation Gauge Cools: What's Driving Markets Friday?

    12/22/23 1:04:24 PM ET
    $ANSS
    $BMY
    $IBB
    $KRTX
    Computer Software: Prepackaged Software
    Technology
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ANSS alert in real time by email

    The S&P 500 and Nasdaq 100 indices are on the verge of achieving an impressive eight consecutive weeks of gains following a more significant decline than expected in the Federal Reserve’s favored inflation gauge in November, the Personal Consumption Expenditures (PCE) price index.

    For the S&P 500, this marks its longest run of positive weekly closes since September 2017, while for the Nasdaq 100, it’s the longest since January 2019.

    Additionally, economic data unveiled on Friday showed consumer spending to be softer than anticipated, along with a positive revision to the Michigan Consumer Sentiment Index and durable goods orders that surpassed expectations.

    The iShares Russell 2000 ETF (NYSE:IWM), tracking small-cap stocks, continues to outshine its large-cap counterparts.

    Notably, both the U.S. Dollar Index, tracked by the Invesco DB USD Index Bullish Fund ETF (NYSE:UUP), and Treasury yields remained steady throughout the day.

    Gold, represented by the SPDR Gold Trust (NYSE:GLD), experienced a modest 0.4% uptick, reaching $2,050 per ounce, while Bitcoin (CRYPTO: BTC) recorded a slight 0.5% decline. WTI oil maintained its position at $74 per barrel.

    Chart of The Day: Fed’s Preferred Gauge of Inflation Further Cools In November

    Friday’s Performance In US Major Indices, ETFs

    IndexPricePercentage Change (%)
    Russell 20002,037.731.0%
    Nasdaq 10016,804.060.3%
    S&P 5004,761.140.3%
    Dow Jones37,433.560.2%

    The SPDR S&P 500 ETF Trust (NYSE:SPY) was 0.3% higher to $474.28, the SPDR Dow Jones Industrial Average ETF (NYSE:DIA) was 0.1% higher to $374.41 and the Invesco QQQ Trust (NASDAQ:QQQ) inched up 0.3% to $409.02, according to Benzinga Pro data.

    Sector-wise, staples and utilities outperformed, with both the Consumer Staples Select Sector SPDR Fund (NYSE:XLP) and the Utilities Select Sector SPDR Fund (NYSE:XLU) up 0.9%.

    The Consumer Discretionary Select Sector SPDR Fund (NYSE:XLY) was the only sector in the red, down 0.3%.

    Among industries, the iShares Biotechnology ETF (NYSE:IBB) rose 3.6%, followed by the VanEck Gold Miners ETF (NYSE:GDX).

    Friday’s Stock Movers

    • ANSYS, Inc. (NASDAQ:ANSS) surged by 12% following a Reuters report that the company is considering various options, including a possible sale. This decision comes in response to takeover interest from potential buyers, as disclosed by sources familiar with the matter.
    • NIKE Inc. (NYSE:NKE) fell 10%, after the company missed revenue estimates last quarter and announced weaker-than-expected guidance due to declining sales from Greater China.
    • Brystol Myers Squib (NYSE:BMY) rose 2.2% after the company agreed to buy Karuna Therapeutics (NASDAQ:KRTX) for $14 billion in cash, gaining a promising experimental schizophrenia drug. KRTX rose 47%.
    • Moderna Inc. (NASDAQ:MRNA) surged 5%, on track for its sixth straight week of gains.

    Read now: Is Lower Inflation A Green Light For 2024 Interest Rate Cuts? Markets Are Ending The Year ‘Surprised,’ CIO Says

    Photo via Shutterstock.

    Get the next $ANSS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ANSS
    $BMY
    $IBB
    $KRTX

    CompanyDatePrice TargetRatingAnalyst
    Nike Inc.
    $NKE
    3/11/2026$73.00Equal Weight → Overweight
    Barclays
    Bristol-Myers Squibb Company
    $BMY
    2/25/2026$60.00Sector Perform
    RBC Capital Mkts
    Bristol-Myers Squibb Company
    $BMY
    2/20/2026$75.00Overweight
    Barclays
    Moderna Inc.
    $MRNA
    1/28/2026$25.00Equal Weight
    Barclays
    Nike Inc.
    $NKE
    1/8/2026Hold
    Deutsche Bank
    Nike Inc.
    $NKE
    1/8/2026Buy → Hold
    Needham
    Moderna Inc.
    $MRNA
    1/7/2026$34.00Neutral
    UBS
    Bristol-Myers Squibb Company
    $BMY
    1/7/2026$65.00Neutral → Buy
    UBS
    More analyst ratings

    $ANSS
    $BMY
    $IBB
    $KRTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    DICK'S Sporting Goods and NIKE, Inc. Enlist Dave "Lil Dicky" Burd and Diana Taurasi to Find the Next Generation of Hoopers with "The Scouts Are Out" Campaign

    Also featured are Jayson Tatum, Sabrina Ionescu, Shai Gilgeous-Alexander, Stephon Castle and Tyran StokesPITTSBURGH, March 17, 2026 /PRNewswire/ -- Today, DICK'S Sporting Goods (NYSE:DKS), in collaboration with NIKE, Inc. (NYSE:NKE), unveiled "The Scouts are Out", a new campaign launching ahead of basketball's biggest month. Built around an unexpected, yet logical idea – the best place to scout the game's top talent is DICK'S – the campaign consists of a series of videos that feature a roster of Nike, Jordan Brand and Converse athletes, and highlights March as a pivotal time when young hoopers showcase their skills and rise in the ranks.   In the anthem spot, which

    3/17/26 12:00:00 PM ET
    $DKS
    $NKE
    Other Specialty Stores
    Consumer Discretionary
    Shoe Manufacturing

    Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma

    Study marks the first positive Phase 3 study for mezigdomide and the second positive Phase 3 study for the Bristol Myers Squibb CELMoD program Bristol Myers Squibb (NYSE:BMY) today announced positive interim Phase 3 results from the SUCCESSOR-2 study (NCT05552976). In the trial, oral mezigdomide in combination with carfilzomib and dexamethasone (MeziKd) demonstrated statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus carfilzomib and dexamethasone alone (Kd) in patients with relapsed or refractory multiple myeloma (RRMM). Safety findings were consistent with the known profile of mezigdomide and the combination regimen. Patients will con

    3/9/26 6:59:00 AM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    U.S. FDA Approves Bristol Myers Squibb's Sotyktu® (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis

    Significantly more patients treated with once-daily, oral Sotyktu achieved an ACR20 response compared with placebo at Week 16 in the pivotal Phase 3 POETYK PsA-1 and POETYK PsA-2 clinical trials Sotyktu is the first and only tyrosine kinase 2 (TYK2) inhibitor to be approved for this indication Bristol Myers Squibb (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved Sotyktu® (deucravacitinib) for the treatment of adults with active psoriatic arthritis (PsA).1 Sotyktu, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, is the first TYK2 inhibitor to be approved for PsA. "Today's announcement marks the introduction of a new, differentiated option

    3/6/26 9:59:00 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANSS
    $BMY
    $IBB
    $KRTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    NIKE upgraded by Barclays with a new price target

    Barclays upgraded NIKE from Equal Weight to Overweight and set a new price target of $73.00

    3/11/26 8:29:15 AM ET
    $NKE
    Shoe Manufacturing
    Consumer Discretionary

    RBC Capital Mkts initiated coverage on Bristol-Myers with a new price target

    RBC Capital Mkts initiated coverage of Bristol-Myers with a rating of Sector Perform and set a new price target of $60.00

    2/25/26 7:49:08 AM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Bristol-Myers with a new price target

    Barclays initiated coverage of Bristol-Myers with a rating of Overweight and set a new price target of $75.00

    2/20/26 8:24:06 AM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANSS
    $BMY
    $IBB
    $KRTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    PRESIDENT & CEO Hill Elliott bought $1,001,307 worth of Class B Common Stock (16,388 units at $61.10), increasing direct ownership by 7% to 241,587 units (SEC Form 4)

    4 - NIKE, Inc. (0000320187) (Issuer)

    12/30/25 4:23:10 PM ET
    $NKE
    Shoe Manufacturing
    Consumer Discretionary

    Director Cook Timothy D bought $2,948,500 worth of Class B Common Stock (50,000 units at $58.97), increasing direct ownership by 90% to 105,480 units (SEC Form 4)

    4 - NIKE, Inc. (0000320187) (Issuer)

    12/23/25 4:25:32 PM ET
    $NKE
    Shoe Manufacturing
    Consumer Discretionary

    Director Swan Robert Holmes bought $500,080 worth of Class B Common Stock (8,691 units at $57.54), increasing direct ownership by 25% to 43,293 units (SEC Form 4)

    4 - NIKE, Inc. (0000320187) (Issuer)

    12/23/25 4:21:15 PM ET
    $NKE
    Shoe Manufacturing
    Consumer Discretionary

    $ANSS
    $BMY
    $IBB
    $KRTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by President, RayzeBio Org. Hickey Benjamin

    4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

    3/12/26 4:24:46 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by EVP, Chief Strategy Officer Shibutani Hiroshi Chris

    4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

    3/12/26 4:23:48 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by EVP,Chief Med Offr,Head of Dev Massacesi Cristian

    4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

    3/12/26 4:23:04 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANSS
    $BMY
    $IBB
    $KRTX
    SEC Filings

    View All

    SEC Form DEF 14A filed by Moderna Inc.

    DEF 14A - Moderna, Inc. (0001682852) (Filer)

    3/16/26 4:31:50 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form DEFA14A filed by Moderna Inc.

    DEFA14A - Moderna, Inc. (0001682852) (Filer)

    3/16/26 4:32:27 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Nike Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - NIKE, Inc. (0000320187) (Filer)

    3/9/26 4:33:25 PM ET
    $NKE
    Shoe Manufacturing
    Consumer Discretionary

    $ANSS
    $BMY
    $IBB
    $KRTX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    September 26, 2024 - FDA Approves Drug with New Mechanism of Action for Treatment of Schizophrenia

    For Immediate Release: September 26, 2024 Today, the U.S. Food and Drug Administration approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults. It is the first antipsychotic drug approved to treat schizophrenia that targets cholinergic receptors as opposed to dopamine receptors, which has long been the standard of care.   “Schizophrenia is a leading

    9/26/24 6:42:20 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    June 14, 2024 - FDA Roundup: June 14, 2024

    For Immediate Release: June 14, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued a proposed exemption for certain cottage cheese products from the requirements of the Food Traceability Rule. The proposal would exempt Grade “A” cottage cheese that appears on the Interstate Milk Shippers List from the requirements of the r

    6/14/24 3:54:45 PM ET
    $MMSI
    $BMY
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    March 8, 2024 - FDA Roundup: March 8, 2024

    For Immediate Release: March 08, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced proposed new regulations to provide animal drug sponsors with predictable requirements for the labeling of prescription and over-the-counter new animal drugs, as well as new animal drugs for use in animal feeds. The proposed content and

    3/8/24 3:26:46 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANSS
    $BMY
    $IBB
    $KRTX
    Financials

    Live finance-specific insights

    View All

    Bristol Myers Squibb Announces Dividend

    Bristol Myers Squibb (NYSE:BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-three cents ($0.63) per share on the $0.10 par value common stock of the company. The dividend is payable on May 1, 2026, to stockholders of record at the close of business on April 2, 2026. About Bristol Myers Squibb: Transforming Patients' Lives Through Science At Bristol Myers Squibb, our mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define what's possible for the future of medicine and the patients we serve. For more information about Bristol Myers Squibb, visit u

    3/2/26 4:16:00 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    UPDATE: NIKE, Inc. Announces Third Quarter Fiscal 2026 Earnings and Conference Call

    To accommodate for several holidays, NIKE, Inc. (NYSE:NKE) now plans to release its third quarter fiscal 2026 financial results on Tuesday, March 31, 2026, at approximately 1:15 p.m. PT, following the close of regular stock market trading hours. Following the news release, NIKE, Inc. management will host a conference call beginning at 2:00 p.m. PT to review results. The conference call will be broadcast live over the Internet and can be accessed at https://investors.nike.com/. For those unable to listen to the live broadcast, an archived version will be available at the same location through 9:00 p.m. PT, April 23, 2026. About NIKE, Inc. NIKE, Inc., headquartered in Beaverton, Oregon,

    2/27/26 3:58:00 PM ET
    $NKE
    Shoe Manufacturing
    Consumer Discretionary

    NIKE, Inc. Announces Third Quarter Fiscal 2026 Earnings and Conference Call

    NIKE, Inc. (NYSE:NKE) plans to release its third quarter fiscal 2026 financial results on Thursday, April 2, 2026, at approximately 1:15 p.m. PT, following the close of regular stock market trading hours. Following the news release, NIKE, Inc. management will host a conference call beginning at 2:00 p.m. PT to review results. The conference call will be broadcast live over the Internet and can be accessed at https://investors.nike.com/. For those unable to listen to the live broadcast, an archived version will be available at the same location through 9:00 p.m. PT, April 23, 2026. About NIKE, Inc. NIKE, Inc., headquartered in Beaverton, Oregon, is the world's leading designer, markete

    2/26/26 5:00:00 PM ET
    $NKE
    Shoe Manufacturing
    Consumer Discretionary

    $ANSS
    $BMY
    $IBB
    $KRTX
    Leadership Updates

    Live Leadership Updates

    View All

    Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board

    WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"), a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced it has appointed François Nader, M.D., MBA, as an independent director to its Board of Directors, effective April 1, 2026, at which time he will also assume the role of Chair of the Board. Dr. Nader brings more than 30 years of leadership experience across the biotechnology and pharmaceutical industry and currently serves as an Independent Director of Moderna, Inc. (NASDAQ:MRNA), a glo

    2/23/26 4:01:00 PM ET
    $MRNA
    $TECX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vuori Appoints Andrew Campion to Board of Directors

    The addition of the industry leader reinforces the brand's continued momentum and further fuels its strategic growth priorities Vuori, the performance and lifestyle brand known for its coastal California-inspired style, today announced the appointment of Andrew Campion to its Board of Directors and a member of its Audit Committee. For over 17 years, Andy served in executive leadership roles at Nike Inc. (NYSE:NKE), including as Chief Operating Officer, Chief Financial Officer, and head of global strategy. Prior to Nike, Campion was with The Walt Disney Company (NYSE:DIS), serving as its Senior Vice President of Corporate Development. Currently, Andy is the Chairman and CEO of Unrivaled

    9/15/25 6:00:00 AM ET
    $DIS
    $NKE
    $SBUX
    Services-Misc. Amusement & Recreation
    Consumer Discretionary
    Shoe Manufacturing
    Restaurants

    Ajit Singh Appointed CEO of Harbinger Health and CEO-Partner of Flagship Pioneering

    Stephen Hahn to Transition to CEO Emeritus and Special Advisor and remain on Harbinger's board CAMBRIDGE, Mass., Aug. 11, 2025 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Harbinger Health, a biotechnology company pioneering the detection of early cancer, today announced the appointment of Ajit Singh, Ph.D. as CEO-Partner of Flagship and the new CEO of Harbinger.  Dr. Singh, a veteran of the diagnostics industry, will also continue as a Harbinger board member, a role he has held since 2024. Dr. Singh succeeds Stephen Hahn, M.D., who will transition from his role as CEO and remain closely involved with the company as CEO Emeritus and Special Advisor. He will co

    8/11/25 12:00:00 PM ET
    $FHTX
    $MRNA
    $SANA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $ANSS
    $BMY
    $IBB
    $KRTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Moderna Inc. (Amendment)

    SC 13G/A - Moderna, Inc. (0001682852) (Subject)

    4/10/24 2:03:52 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Karuna Therapeutics Inc.

    SC 13G - Karuna Therapeutics, Inc. (0001771917) (Subject)

    2/14/24 10:04:40 AM ET
    $KRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Karuna Therapeutics Inc. (Amendment)

    SC 13G/A - Karuna Therapeutics, Inc. (0001771917) (Subject)

    2/14/24 10:03:02 AM ET
    $KRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care